Suven Life Sciences Q1 FY27 results: consolidated net loss widens to about Rs 127.61 cr

Revenue growth above 20%Net loss reportedResults View source PDF Explain this filing

SUVEN · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-4.0%Reaction day

₹327.15

prior close

₹319.30

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.4%-4.4% vs market

Healthcare Research Analytics & Technology peers, median of 5sector-0.4%-3.6% vs sector

On the reaction day the stock moved 4.4 pts less than Nifty Microcap 250 and 3.6 pts less than its Healthcare Research Analytics & Technology peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-2.3

10m

-1.9

15m

-1.9

30m

-2.4

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-4.0+0.4-4.4-0.4-3.6

Next day

-2.9+0.4-3.3+0.6-3.5

+2.1+0.3+1.8+0.6+1.5

+4.4+0.2+4.3+2.9+1.6

+0.6+0.5+0.0+4.4-3.8

-0.6+0.7-1.3+5.0-5.7

+1.5+0.9+0.6+2.4-1.0

15d

+12.3+1.6+10.6+1.5+10.8

+15.2+2.4+12.8-3.5+18.7

-5.0+1.1-6.2-11.1+6.0

—————

UpDownMarket · Nifty Microcap 250Sector · Healthcare Research Analytics & Technology peers, median of 5Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Suven Life Sciences reported a consolidated net loss of Rs 12,761 lakhs for Q1 FY27 versus a loss of Rs 5,152 lakhs in the year-ago quarter, driven by a sharp rise in R&D expenses to Rs 12,383 lakhs from Rs 4,149 lakhs. Standalone net loss was Rs 1,612 lakhs. Revenue from operations grew to Rs 357 lakhs from Rs 187 lakhs YoY. Clinical pipeline advanced with SUVN-502 reaching 95 percent enrollment in global Phase 3 trial. Auditor issued an unmodified review report.

Likely market impact

Wider losses as R&D spend ramps up for Phase 3 trials; sustained clinical pipeline progress is the key positive for long-term value.